

ASX Release

Oventus presentation for AGM of Thorney Technologies Ltd

Brisbane, Australia 24th November 2017: Oventus Medical Ltd (ASX: OVN) is pleased to release a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors at the Annual General Meeting of Thorney Technologies Ltd (ASX: TEK) today in Melbourne.

Dr Chris Hart said “We are lucky to be supported by an institution with the pedigree of Thorney. We’ve had an incredible response following Thorney’s Chairman, Alex Waislitz’s presentation on Oventus at last week’s Sohn Hearts and Minds conference in Sydney and are grateful of the opportunity to present directly to investors today.”

About the Oventus O₂Vent airway technology

The Oventus O₂Vent is an oral appliance device which brings the lower jaw forward (a process commonly referred to as mandibular advancement) and incorporates an opening to the oral cavity to allow breathing through the device airway, minimising pressure swings during sleep.

Further information can be found on our website: <http://oventus.com.au/how-it-works/>.

—ENDS—

For more information, please contact:

Mr Neil Anderson, Managing Director and CEO: M: 0403 003 475

Jane Lowe, IR Department: M: 0411 117 774 or jane.lowe@irdepartment.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O₂Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.



BETTER SLEEP, BETTER HEALTH *and a* BETTER LIFE

A clinical study completed earlier this year showed the company's first generation product, the O₂Vent Mono™, is successful in treating Obstructive Sleep Apnoea (OSA) and that snoring was either eliminated or significantly reduced to 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*



Oventus: Innovators in Sleep Apnoea Treatment

Presentation to investors at
the 2017 AGM of Thorney
Technologies Ltd (ASX:
TEK)

November 2017



About Oventus (ASX: OVN)

Oventus is commercializing its O₂Vent technology to treat Obstructive Sleep Apnoea

Our titanium, 3D printed airway technology “O₂Vent” enhances treatment outcomes **for more than half** of OSA patients






Without the need
for one of these



Obstructive sleep apnoea...
more than just a poor night's sleep

**OSA impacts the way
people breathe when they
are sleeping.**

**Breathing is briefly
interrupted or becomes very
shallow during sleep.**

A light gray world map with several colored location pins: three blue pins in North America, Europe, and Asia; and two orange pins and one dark blue pin in Australia. The text "Poor sleep has major impacts on health economics" is centered over the map.

Poor sleep has major impacts on health economics

80%

Number of sleep apnoea sufferers understood to be out of care right now

\$26.2
BILLION

Financial losses in Australia between 2016-2017 from inadequate sleep

\$40.1
BILLION


Australia attributed \$40.1 billion to loss of well-being in 2016-2017

The big business of sleep

A young couple is lying in bed. The woman, on the left, has her eyes closed and her mouth is open as if she is breathing through her mouth while sleeping. The man, on the right, is looking towards the camera with a thoughtful or slightly concerned expression. They are both under a light blue and white striped duvet cover.

Obstructive Sleep Apnoea (OSA) is a massive market.
It is worth US\$3.8** globally, growing at a CAGR of 15-20%.

** In 2015: Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98.



Only 20% of OSA sufferers
are in care.

Why?

Their inability to tolerate
conventional treatment.



Does this look comfortable to you?

How Oventus Airway technology works

The O₂Vent technology is the first major innovation in the treatment of sleep apnoea for years

1.

Air goes in through the airway on inhalation and out through the airway on exhalation.

Acts like a “second nose” when patient’s mouth is closed. An open mouth is undesirable when sleeping as an open jaw can cause breathing obstruction in the throat.




2.

Air in on inhalation delivered to throat, air out on exhalation

3.

The device brings the lower jaw forward, making more room for air to go into the patient’s lungs



Compelling clinical data

In clinical trials (and in real life) our devices succeeded where others could not.

Oventus Airway Technology:

- Makes mouth guards 30-50% more efficacious, and
- Dramatically reduces CPAP pressures and eliminates the need for masks, which
- Delivers significant competitive advantages for half of the current mouth guard and mask market of \$3.8billion/year, and

With the ability to bring more patients into care may well dramatically increase this addressable market



100%

Patients experienced significant improvement in snoring using O₂Vent



82%

Patients experienced complete elimination of snoring using O₂Vent



76%

Patients decreased their Apnoea-Hypopnea Index (AHI) using O₂Vent

With Oventus' oral device, many patients reported a good night's sleep...
*for the first time in **decades.***



Distribution agreement with Modern Dental Group... the world's largest distributor of dental prosthetics

MODERN DENTAL GROUP LOCATIONS



Modern Dental is listed on HKSE

Ticker: 3600 | Market cap: \$2.21 b

Has 25% coverage of all dentists in USA
(34,000 dental offices through subsidiary, Microdental)

Top 3 market share in all major European countries

Australia's largest dental laboratory network

70+ sales and customer service centres overseas

Focus on custom-made prostheses

Oventus' range is **the only premium device range** that Modern will sell

Corporate snapshot

Oventus Medical Limited: ASX:OVN

Capital Structure

Shares on Issue	92.1m
Options	3.84m
Price (22/11/17)	\$0.61
Market Cap	\$56.20m

Cash on hand (30/6/17)	\$8,663,000
Revenue FY17	\$447,994





“I HAVE USED THE OVENTUS DEVICE FOR 3 YEARS AND IT IS AMAZING.

No snoring and so easy to carry around. Used it right through Europe and did not have to worry about electricity or extra bags. Used a CPAP for 20 years. Now I am so free from all that. I love it!”

Jeanne Marshall

See more at www.oventus.com.au